Evidence map›Paper›PMID 38665145›Full record

ArticleCase reports in gastroenterology

Severe Hepatitis Complicating Olmesartan Enteropathy: A Case Report.

Ruyi Tan, Joshua Haron Abasszade, Hardesh Dhillon, Chih Chien Kuan, Thomas Worland, Shireen Tabatabai

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ruyi TanDepartment of Gastroenterology and Hepatology, Monash Health, Melbourne, VIC, Australia.
Joshua Haron AbasszadeDepartment of Gastroenterology and Hepatology, Monash Health, Melbourne, VIC, Australia.
Hardesh DhillonDepartment of Gastroenterology and Hepatology, Monash Health, Melbourne, VIC, Australia.
Chih Chien KuanDepartment of Anatomical Pathology, Monash Health, Melbourne, VIC, Australia.
Thomas WorlandDepartment of Gastroenterology and Hepatology, Monash Health, Melbourne, VIC, Australia.
Shireen TabatabaiDepartment of Gastroenterology and Hepatology, Monash Health, Melbourne, VIC, Australia.
Monash Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Olmesartan, an angiotensin II receptor antagonist, is associated with an uncommon complication of enteropathy that presents insidiously, usually months to years after initial commencement of anti-hypertensive therapy which can be dose-dependent. It has a variable spectrum of clinical presentation but commonly presents as a moderate to severe malabsorptive process with potential severe complications related to poor end-organ perfusion. Lymphocytic gastritis and microscopic colitis are often noted in patients presenting with olmesartan-induced enteropathy; however, hepatic involvement has been less frequently observed. Case Presentation: We illustrate a case of a 43-year-old female presenting with 2 weeks of profuse non-bloody diarrhea in the context of olmesartan enteropathy which was complicated by an acute severe ischemic and enteropathic hepatopathy. Conclusion: Our case prompts clinicians to maintain a high index of suspicion in cases presenting with a seronegative enteropathy and concurrent acute liver injury while on olmesartan therapy. Cessation of olmesartan therapy resulted in prompt resolution of diarrheal symptoms and normalization of the acute transaminitis on subsequent three-week follow-up.

Indexed as

Acute hepatitisCase reportEnteropathyIschemic hepatitisOlmesartan

Identifiers

PMID38665145
PMCPMC11045212
OpenAlexW4395677501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.